ASHA 624
Alternative Names: ASHA-624Latest Information Update: 03 Apr 2024
At a glance
- Originator Asha Therapeutics
- Class Antiglaucomas; Neuroprotectants
- Mechanism of Action SARM1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis; Glaucoma; Spinal cord injuries
Most Recent Events
- 02 Apr 2024 Pharmacodynamic and adverse events data from a preclinical trial in Amyotrophic lateral sclerosis released by Asha Therapeutics
- 29 Sep 2023 Preclinical trials in Amyotrophic lateral sclerosis in USA (unspecified route) (Asha Therapeutics pipeline, September 2023)
- 29 Sep 2023 Preclinical trials in Glaucoma in USA (unspecified route) (Asha Therapeutics pipeline, September 2023)